Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) EBT Margin (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed EBT Margin for 9 consecutive years, with 10.84% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin rose 80.0% year-over-year to 10.84%, compared with a TTM value of 17.44% through Sep 2025, down 496.0%, and an annual FY2024 reading of 15.4%, up 167.0% over the prior year.
  • EBT Margin was 10.84% for Q3 2025 at Sunshine Biopharma, up from 21.04% in the prior quarter.
  • Across five years, EBT Margin topped out at 783.75% in Q4 2021 and bottomed at 15440.43% in Q1 2021.
  • Average EBT Margin over 5 years is 1650.19%, with a median of 21.04% recorded in 2025.
  • The sharpest move saw EBT Margin tumbled -1459140bps in 2021, then skyrocketed 1443245bps in 2022.
  • Year by year, EBT Margin stood at 783.75% in 2021, then plummeted by -175bps to 590.86% in 2022, then skyrocketed by 98bps to 13.41% in 2023, then tumbled by -78bps to 23.83% in 2024, then soared by 55bps to 10.84% in 2025.
  • Business Quant data shows EBT Margin for SBFM at 10.84% in Q3 2025, 21.04% in Q2 2025, and 13.71% in Q1 2025.